[111in]-fpi-1547
mAbexperimentalImaging agent
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 17, 2019 (NCT03746431)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Adrenocortical Carcinoma · Phase 1
- Antineoplastic Agents · Phase 1
- Breast Neoplasms · Phase 1
- Drugs, Investigational · Phase 1
- Endometrial Neoplasms · Phase 1
- Immunoconjugates · Phase 1
- Melanoma · Phase 1
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Uterine Cervical Neoplasms · Phase 1
Mechanism of action
IGF1R inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Imaging
- 111-indium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03746431 | Phase 1 | Jan 17, 2019 | Fusion Pharma LLC |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fusion Pharma LLC | For profit | 1 | 1 | 1 | 2019 |
1 organizations
Page 1 / 1